article thumbnail

Stem cell therapy shows promise in advanced MS

Drug Discovery World

An international team of scientists has shown that a stem cell therapy for multiple sclerosis (MS) could prevent further damage to the brain. This was a very small, early-stage study and we need further clinical trials to find out if this treatment has a beneficial effect on the condition.

Therapies 264
article thumbnail

Non-viral gene therapy shows early efficacy in lung cancer

Drug Discovery World

Positive Phase I trial data indicates that Reqorsa (quaratusugene ozeplasmid) has shown early efficacy for the treatment of non-small cell lung cancer (NSCLC). The data will be presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

Therapies 277
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Treatment potential for immunotherapy-induced cytokine release syndrome  

Drug Discovery World

Market opportunity estimated at over US$1 billion Largely due to the CRS risk (which can be life threatening), administration of cancer immunotherapies, such as bispecific antibodies, is currently restricted to specialist cancer centres which limits uptake of these therapies.

Treatment 162
article thumbnail

How ready are we for radioligand therapies?  

Drug Discovery World

DDW Editor Reece Armstrong speaks to Jasminka Taleska , Director, RLT HCS Readiness and Policy at Novartis, about the opportunities radioligand therapies (RLTs) represent in treating cancer patients. Its unique mechanism of action aims to deliver treatment directly to cancer cells, minimising damage to nearby healthy cells 2,5.

Therapies 147
article thumbnail

International consortium launches €12.8 million lung cancer project

Drug Discovery World

Over the next three years, the consortium will progress the development of a regenerative gene therapy for lung cancer. . The new treatment will use OmniSpirant’s OmniSom technology to develop an inhaled regenerative gene therapy. The post International consortium launches €12.8

article thumbnail

Orphan Drug Designation for first-in-class autotaxin cancer therapy

Drug Discovery World

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to iOnctura for its autotaxin inhibitor cambritaxestat for the treatment of pancreatic cancer. Following a separate submission process the World Health Organization has proposed the International Nonproprietary Name (INN) of cambritaxestat.

Therapies 173
article thumbnail

Collaborators investigate novel T-cell receptor therapy

Drug Discovery World

Elicera Therapeutics has entered a Material Transfer Agreement (MTA) with a prominent US cancer centre to evaluate the enhancing effect of the iTANK-technology in a novel T-cell receptor therapy targeting skin cancer and lung cancer.

Therapies 130